The first trial will evaluate whether the HPV 9-valent vaccine (Gardasil 9, Merck) can prevent oral HPV infections among men with HIV.
The second trial will focus on rapid “point-of-care” screening tests to help detect cervical premalignant lesions.
The third trial will evaluate the effectiveness of a novel therapeutic HPV vaccine for .
The co-principal investigators are Timothy Wilkin, MD, associate professor of medicine in the division of infectious diseases at Weill Cornell Medicine and infectious disease specialist at NewYork-Presbyterian/Weill Cornell Medical Center; Anna R. Giuliano, PhD, founding director of Center for Immunization and Infection Research in Cancer at Moffitt Cancer Center; and Luisa Lina Villa, PhD, associate professor in the department of radiology and oncology at Universidade de São Paulo.The three institutions comprise the Multinational Partnership to Prevent HPV-Associated Cancer in People Living with HIV: Brazil, Mexico, Puerto Rico, which is part of NCI’s U.S.-Latin American-Caribbean Clinical Trials Network. The network joins institutions in the U.S. with those in low- and middle-income countries in the Caribbean and Latin America to conduct multidisciplinary trials.